Back to top
more

Omnicell (OMCL)

(Real Time Quote from BATS)

$31.52 USD

31.52
133,928

+0.69 (2.24%)

Updated Aug 12, 2025 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 245)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Omnicell (OMCL) To Your Portfolio

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its better-than-expected results in the third quarter and robust segmental performance.

Zacks Equity Research

Walgreens (WBA) to Offer COVID-19 Vaccine Booster Shots

by Zacks Equity Research

Individuals aged 18 years or older are eligible to avail Pfizer, Moderna or Johnson & Johnson COVID-19 vaccine boosters from Walgreens' (WBA) stores.

Zacks Equity Research

NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NXGN vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJR

Zacks Equity Research

Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VIOO

Zacks Equity Research

Should SPDRSP6 SC (SLY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLY

Zacks Equity Research

Should SPDRSP6 SC (SLY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLY

Zacks Equity Research

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

by Zacks Equity Research

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.

Zacks Equity Research

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed

by Zacks Equity Research

Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.

Zacks Equity Research

QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up

by Zacks Equity Research

QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.

Zacks Equity Research

Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up

by Zacks Equity Research

Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.

Zacks Equity Research

Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up

by Zacks Equity Research

Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.

Zacks Equity Research

NXGN or OMCL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NXGN vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

Omnicell (OMCL) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 18.68% and 4.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Earnings on Nov 2: IDXX, STE & More

by Urmimala Biswas

With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.

Zacks Equity Research

Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJT

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Omnicell (OMCL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLYG

Zacks Equity Research

Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up

by Zacks Equity Research

Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.

Zacks Equity Research

Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.

Zacks Equity Research

Intuitive Surgical (ISRG) Q3 Earnings Match Estimates, Up Y/Y

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.

Zacks Equity Research

CNVY vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CNVY vs. OMCL: Which Stock Is the Better Value Option?